JSPR Jasper Therapeutics, Inc. Insider Trading

CEO Ron Martell bought 41,000 shares at $2.43; stock down 90.6% YTD; 3 other insiders also bought in past 14 days

MARTELL RON, President and CEO, purchased 41,000 shares at $2.43, increasing his holdings by 123.8% to 74,118 shares—a significant personal investment at a severe valuation discount. The stock has collapsed 90.6% from its 52-week high of $24.73 and declined 59.0% over the past 90 days, indicating pronounced shareholder distress. Notably, this purchase is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting aligned management perception at current levels. The company reported negative net income of $-26,723,000.00 and holds a market cap of $37,870,263.56, placing this transaction in the context of an unprofitable biotech facing operational headwinds. The concentrated buying by multiple insiders at depressed levels warrants investor scrutiny into whether the market is overreacting or whether insiders possess material non-public information about near-term value recovery.

Director WIGGANS THOMAS G bought 41,000 shares of JSPR at $2.43; stock down -90.6% from 52-week high amid 3 other insider buys in 14 days.

Director Wiggans purchased 41,000 shares at $2.43, establishing an initial position, while the stock trades at $2.33 — down -90.6% from its 52-week high of $24.73 and -59.0% over the past 90 days. The timing comes during a cluster of 4 insider buys within 14 days, suggesting coordinated appetite despite the company's $-26.7M net loss and $37.9M market cap. Wiggans' cross-ticker track record shows 100% win rate on prior buys with avg 90d return of +2923.1%; his prior 5 trades at JSPR each posted triple-digit 90-day gains (range +2830.4% to +3106.9%), all well-timed. The current purchase occurs at depressed absolute price levels after a steep drawdown, but the unprofitable fundamentals and heavy capital losses relative to market cap distinguish this setup from his prior profitable entries.

Director Lucas Svetlana buys 20,000 shares of JSPR at $2.43 amid 3-insider cluster; stock down 90.6% from 52-week high of $24.73

Lucas Svetlana, a director, purchased 20,000 shares at $2.43 on 2025-09-22, establishing a new position worth $48,600.00. This transaction is part of a cluster pattern with 3 other insiders buying within the past 14 days. The stock is trading at a severe discount to its 52-week high of $24.73 (currently $2.33, down 90.6%), having declined 59.0% over 90 days and 21.3% over 30 days. Jasper Therapeutics reported a net loss of $26.7M in its most recent fiscal year with a market cap of $37.9M, indicating material unprofitability. The convergence of multiple insider purchases at depressed valuations alongside pronounced losses and significant downward price momentum warrants close examination of the company's operational trajectory and near-term catalysts.

Director Shizuru Judith Anne bought 41,000 shares of JSPR at $2.43; stock down -90.6% from 52-week high; 3 other insiders also buying in 14-day window

Director Shizuru Judith Anne purchased 41,000 shares at $2.43, increasing her holdings by 35.4% from 115,901 to 156,901 shares. The stock is trading at $2.33, representing a -90.6% decline from its 52-week high of $24.73 and down -59.0% over the past 90 days. Notably, 3 other insiders have also purchased within the past 14 days, forming a cluster buy pattern. The company reported a net income of -$26,723,000 over its most recent fiscal year, indicating ongoing unprofitability, and carries a market cap of $37,870,263.56. This coordinated accumulation at deeply depressed price levels by multiple insiders warrants investor attention as a potential signal of management's view on risk/reward at current valuations.